InvestorsHub Logo
Post# of 252502
Next 10
Followers 3
Posts 147
Boards Moderated 0
Alias Born 07/16/2006

Re: iwfal post# 137315

Saturday, 02/18/2012 1:49:16 PM

Saturday, February 18, 2012 1:49:16 PM

Post# of 252502
"Given the size of the T2D market I find it very odd how few of these targets are being explored by big pharma."

This is not true. Most of the targets big pharma working on are at very early stage (Discovery stage). I know for sure that more than 15 different targets are being worked on currently.

Some of them are: CCR2 antagonists, GDIR (or GPR119) agonists, GPR120, GPR140, peripheral CB1, etc,.

The probelm with these targets are, they show very good potency and efficacy in preclinical species, but in clinic they are all duds.

One target, GCGR is very potent and efficacious, but issues with elevated liver enzymes since it is directly working on liver.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.